Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.

Trial Details

NCT ID
NCT06971380
Phase
PHASE2
Sponsor
Polina Stepensky
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • HBI0101 CART
Locations (sample)
  • Jerusalem, Israel|31.76904,35.21633

Key Eligibility Criteria

  • ≥18 years of age at the time of signing informed consent.
  • Voluntarily signed informed consent form.
  • Diagnosis of multiple myeloma and/or light-chain amyloidosis with relapsed or refractory disease, with measurable disease at screening visit
  • Subject suffering from multiple myeloma must have been exposed to at least two prior lines of therapy including proteasome inhibitor, immunomodulat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →